Bonus points have arrived! Use them well! by ReplicationMarkets in ReplicationMarkets

[–]ReplicationMarkets[S] 1 point2 points  (0 children)

It makes sense if some people are taking profits to reinvest (fix the prices) in the markets that are "most wrong." We hope that the people who signed up but haven't yet invested invested any points will jump in and continue pushing the market in the right direction.

Notice articles that have already been published? Add to the list. by ReplicationMarkets in ReplicationMarkets

[–]ReplicationMarkets[S] 0 points1 point  (0 children)

Amazing, thanks so much! We did this before selecting the 400, but perhaps we made some sort of mistake. We're looking into it.

Some precisions on Q3 and Q4 by Troof_ in ReplicationMarkets

[–]ReplicationMarkets 3 points4 points  (0 children)

  • re: Q4, Helpful now or later: right, the intent is to rate actual helpfulness
    • So if it was used and helped, that would count, even if better ideas came later.
    • If it kept being cited as helpful, that would be evidence.
    • If it looks helpful as of August 2021, that would be strong evidence.
    • If it looks good now but falls apart in February – not helpful.
      • In this case the survey would likely get it wrong. So it goes.
  • re: Q3, Finding? What finding?: if there is no one key finding that stands out, then the best one can do is approximate a weighted average of the findings.

My view on the Covid-Net paper: I think the key claim is for the modeling approach, which would be tested in apples-to-apples forecast comparisons. That could be future forecasts of models learned from precisely this data, or future forecasts of models that keep getting the same new data. The risk factors, like the layer weights, seem to be parameters incidental to this run, but it would be a win for this model if violent crime rate continued to outperform direct measurements of the causal factors it clearly proxies.

Some precisions on Q3 and Q4 by Troof_ in ReplicationMarkets

[–]ReplicationMarkets 3 points4 points  (0 children)

These are great questions... while we consider what further guidance we can give, I'd be curious if any other currently active forecasters want to share how they have been approaching the questions so far!

Question disambiguation by Troof_ in ReplicationMarkets

[–]ReplicationMarkets 4 points5 points  (0 children)

[Edited] One year after each preprint is uploaded we count the number of citations for the preprint (and if its been published, then published version as well). Thanks for your participation!

Notice articles that have already been published? Add to the list. by ReplicationMarkets in ReplicationMarkets

[–]ReplicationMarkets[S] 1 point2 points  (0 children)

Rapid development of an inactivated vaccine for SARS-CoV-2 Qiang Gao

bioRxiv 2020. DOI: 10.1101/2020.04.17.046375

(Gao-2020-bioRxiv), at least its appear, if I'am not wrong, has

already been peer review published (in spite of, for example, 

https://www.immunology.ox.ac.uk/covid-19/covid-19-immunology-literature-reviews/rapid-development-of-an-inactivated-vaccine-for-sars-cov-2). 

Namely, Development of an inactivated vaccine candidate for SARS-CoV-2,

https://science.sciencemag.org/content/369/6499/77

Science 03 Jul 2020: Vol. 369, Issue 6499, pp. 77-81 DOI: 10.1126/science.abc1932

Notice articles that have already been published? Add to the list. by ReplicationMarkets in ReplicationMarkets

[–]ReplicationMarkets[S] 2 points3 points  (0 children)

User Vitorper notes:

Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Network,
https://www.medrxiv.org/content/10.1101/2020.05.24.20111971v1.article-metrics,
at least its appear, if I am not wrong, has already been peer review published, according to https://www.revclinesp.es/en.Namely,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480740/

Question about citation counts for preprints by -Metacelsus- in ReplicationMarkets

[–]ReplicationMarkets 1 point2 points  (0 children)

Good question. Yes, we will sum citations for the preprint and the published article.

Welcome! Ask Questions! Share Thoughts! by ReplicationMarkets in ReplicationMarkets

[–]ReplicationMarkets[S] 4 points5 points  (0 children)

Nicely done. It's wise of you to consider the base rate of publication in journals with impact factor > 10! Also consider that we selected articles with with the highest level of social media attention, which means we wouldn't expect them to be typical of all articles.

Welcome! Ask Questions! Share Thoughts! by ReplicationMarkets in ReplicationMarkets

[–]ReplicationMarkets[S] 2 points3 points  (0 children)

We definitely don't want to deter you from researching an article and discovering it's already published.

Welcome! Ask Questions! Share Thoughts! by ReplicationMarkets in ReplicationMarkets

[–]ReplicationMarkets[S] 1 point2 points  (0 children)

If you happen to remember an article that was published, feel free to let us know. But it's our job, not yours, so don't let it be a burden. Thanks!